Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research Article

Modulation of MAPK ERK1 and ERK2 in VDR-positive and -negative Breast Cancer Cell Lines

T. CORDES, D. DIESING, S. BECKER, K. DIEDRICH, J. REICHRATH and M. FRIEDRICH
Anticancer Research July 2006, 26 (4A) 2749-2753;
T. CORDES
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: t-cordes{at}web.de
D. DIESING
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. BECKER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. DIEDRICH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. REICHRATH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. FRIEDRICH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

1α-25-Dihydroxyvitamin D3 (calcitriol), the biologically active metabolite of vitamin D, is known to regulate calcium and phosphate levels in bone metabolism. It is also known to influence proliferation and differentiation in carcinoma cells mediated by the vitamin D receptor (VDR). The antiproliferative effects of calcitriol are believed to be mediated by the nuclear pathway via binding the activated receptor to vitamin D-responsive elements. This induces the vitamin D-responsive genes. Another possible pathway might be the MAPK-cascade or rapid response pathway. The interaction of calcitriol and the MAP-kinase-cascade was evaluated on VDR-positive MCF-7 cells and VDR-negative MDA-MB-231 breast cancer cells. The cells were incubated with calcitriol solution at 10-7 M and 10-9 M, or ethanol as controls, for up to 48 h. The effects of calcitriol were measured by semi-quantitative Western blotting. Calcitriol stimulated the MAP-kinases ERK1 and ERK2. A biphasic activation was found for calcitriol in VDR-positive cells after incubation for 5 to 20 min and from 2 to 24 h. However, early activation of ERK1 and ERK2 was also demonstrated in VDR-negative cells. In the controls, ethanol also induced the MAPK-cascade at 5 to 10 min. Calcitriol induction was demonstrated after incubation from 2 to 24 h. In conclusion, it seems that the early induction of the MAPK-cascade was independent of the VDR. A calcitriol-induced MAPK activation was shown after 4 h, which may have been caused by activation of the nuclear receptor pathway.

  • MAP-kinases
  • calcitriol
  • breast cancer
  • vitamin D receptor

Footnotes

  • Received December 29, 2005.
  • Revision received May 3, 2006.
  • Accepted May 12, 2006.
  • Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 26, Issue 4A
July-August 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Modulation of MAPK ERK1 and ERK2 in VDR-positive and -negative Breast Cancer Cell Lines
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Modulation of MAPK ERK1 and ERK2 in VDR-positive and -negative Breast Cancer Cell Lines
T. CORDES, D. DIESING, S. BECKER, K. DIEDRICH, J. REICHRATH, M. FRIEDRICH
Anticancer Research Jul 2006, 26 (4A) 2749-2753;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Modulation of MAPK ERK1 and ERK2 in VDR-positive and -negative Breast Cancer Cell Lines
T. CORDES, D. DIESING, S. BECKER, K. DIEDRICH, J. REICHRATH, M. FRIEDRICH
Anticancer Research Jul 2006, 26 (4A) 2749-2753;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Marked Increase of CYP24A1 mRNA Level in Hepatocellular Carcinoma Cell Lines Following Vitamin D Administration
  • Google Scholar
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire